The goal of this clinical trial is to explore the safety and effectiveness of stoma reversal combining bio-mesh placement in patients with high risk of stoma site incisional hernia (SSIH). The main questions it aims to answer are:

• Whether bio-mesh placement is safe for patients with a high risk of SSIH.
• Whether stoma reversal combining bio-mesh placement is a preventive strategy for patients with high risk of SSIH.
• Whether stoma reversal combining bio-mesh placement will trigger other complications.

Participants who are eligible and are enrolled in this study will receive stoma reversal combining bio-mesh placement surgery. After that, they will be followed up for one year to evaluate the occurrence of SSIH and other complications.

Inclusion Criteria:

• Age: 18-75 years old;
• Patients should have colonic prophylactic stoma and have not received reversal yet;
• There are no obvious signs of tumor recurrence or metastasis in tumor patients before stoma resection;
• No serious underlying diseases, can tolerate general anesthesia surgery
• Preoperative ECOG (Eastern Cooperative Oncology Group) physical status score 0/1;
• Preoperative ASA (American Society of Anesthesiologists) grade I-III;
• Without vital organs function failure;
• All patients and their families signed informed consent before surgery.

Exclusion Criteria:

• Incapacitated persons;
• With a history of other types of hernia;
• Those who have had hernia mesh implantation before;
• Those who are allergic to bio-mesh or their components before;
• Combined with other surgeries;
• Severe mental illness;
• Severe respiratory disease;
• Severe liver and kidney insufficiency;
• Those who have absolute contraindications to surgery;
• Suffering from severe bleeding disorders or obvious abnormal coagulation function;
• History of unstable angina or myocardial infarction within 6 months;
• History of cerebral infarction or cerebral hemorrhage within 6 months;
• Continuous intravenous application of glucocorticoid within 1 month;
• The patient has participated or is participating in other clinical studies (within 6 months).